An aggressive buyer is ramping up their accretive M&A strategy in the fragmented nutraceutical (pills, liquids, powders) and nutrition industry. Companies must have strong financials and a minimum of $2 million trailing EBITDA. USA-based only.

Reply to: --@----.com